Stock Analysis

Investors Appear Satisfied With Danaher Corporation's (NYSE:DHR) Prospects

NYSE:DHR
Source: Shutterstock

With a price-to-earnings (or "P/E") ratio of 45.1x Danaher Corporation (NYSE:DHR) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E ratios under 18x and even P/E's lower than 11x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.

While the market has experienced earnings growth lately, Danaher's earnings have gone into reverse gear, which is not great. One possibility is that the P/E is high because investors think this poor earnings performance will turn the corner. If not, then existing shareholders may be extremely nervous about the viability of the share price.

Check out our latest analysis for Danaher

pe-multiple-vs-industry
NYSE:DHR Price to Earnings Ratio vs Industry January 27th 2025
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Danaher.

How Is Danaher's Growth Trending?

In order to justify its P/E ratio, Danaher would need to produce outstanding growth well in excess of the market.

Retrospectively, the last year delivered a frustrating 11% decrease to the company's bottom line. As a result, earnings from three years ago have also fallen 31% overall. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.

Turning to the outlook, the next three years should generate growth of 16% per year as estimated by the analysts watching the company. Meanwhile, the rest of the market is forecast to only expand by 11% each year, which is noticeably less attractive.

In light of this, it's understandable that Danaher's P/E sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

The Bottom Line On Danaher's P/E

While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.

We've established that Danaher maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. At this stage investors feel the potential for a deterioration in earnings isn't great enough to justify a lower P/E ratio. It's hard to see the share price falling strongly in the near future under these circumstances.

Having said that, be aware Danaher is showing 1 warning sign in our investment analysis, you should know about.

You might be able to find a better investment than Danaher. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:DHR

Danaher

Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.

Excellent balance sheet with questionable track record.

Community Narratives

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Fair Value CHF 264.53|75.35300000000001% undervalued
kapirey
kapirey
Community Contributor
Top Pick for Multi-bagger
Fair Value US$44.06|47.367% undervalued
SuEric
SuEric
Community Contributor
Nova Ljubljanska Banka d.d will expect a 11.2% revenue boost driving future growth
Fair Value €148.18|9.232% undervalued
AurediusCapital
AurediusCapital
Community Contributor